Boehringer Ingelheim’s pimobendan
Executive Summary
Company is seeking outlicensing agreement or development partnership for the oral positive inotropic drug treatment for congestive heart failure. Decision is based on the "considerable resources" needed to develop drugs in this class to meet U.S. approval requirements, which "would have conflicted" with other "priority projects" in its pipeline, company explains in a March 9 announcement. If no agreement is reached, B-I will halt development of the drug, which is in Phase III.